Department of Medicine, University of Toronto, Toronto, Ontario.
Department of Medicine, University of Toronto, Toronto, Ontario ; Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario ; Trauma, Emergency and Critical Care Research Program, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario.
Can J Infect Dis Med Microbiol. 2013 Fall;24(3):129-37. doi: 10.1155/2013/141989.
The optimal duration of antibiotic treatment for bloodstream infections is unknown and understudied.
A retrospective cohort study of critically ill patients with bloodstream infections diagnosed in a tertiary care hospital between March 1, 2010 and March 31, 2011 was undertaken. The impact of patient, pathogen and infectious syndrome characteristics on selection of shorter (≤10 days) or longer (>10 days) treatment duration, and on the number of antibiotic-free days, was examined. The time profile of clinical response was evaluated over the first 14 days of treatment. Relapse, secondary infection and mortality rates were compared between those receiving shorter or longer treatment.
Among 100 critically ill patients with bloodstream infection, the median duration of antibiotic treatment was 11 days, but was highly variable (interquartile range 4.5 to 17 days). Predictors of longer treatment (fewer antibiotic-free days) included foci with established requirements for prolonged treatment, underlying respiratory tract focus, and infection with Staphylococcus aureus or Pseudomonas species. Predictors of shorter treatment (more antibiotic-free days) included vascular catheter source and bacteremia with coagulase-negative staphylococci. Temperature improvements plateaued after the first week; white blood cell counts, multiple organ dysfunction scores and vasopressor dependence continued to decline into the second week. Among 72 patients who survived to 10 days, clinical outcomes were similar between those receiving shorter and longer treatment.
Antibiotic treatment durations for patients with bloodstream infection are highly variable and often prolonged. A randomized trial is needed to determine the duration of treatment that will maximize cure while minimizing adverse consequences of antibiotics.
血流感染的最佳抗生素治疗持续时间尚不清楚,也缺乏相关研究。
回顾性分析了 2010 年 3 月 1 日至 2011 年 3 月 31 日期间在一家三级保健医院确诊的血流感染的重症患者队列。研究了患者、病原体和感染综合征特征对选择较短(≤10 天)或较长(>10 天)治疗持续时间的影响,以及对无抗生素天数的影响。评估了治疗开始后前 14 天内的临床反应时间分布。比较了接受较短或较长治疗的患者的复发率、二次感染率和死亡率。
在 100 例血流感染的重症患者中,抗生素治疗的中位持续时间为 11 天,但差异很大(四分位间距为 4.5 至 17 天)。较长治疗(无抗生素天数较少)的预测因素包括需要长期治疗的明确病灶、下呼吸道病灶、金黄色葡萄球菌或铜绿假单胞菌感染。较短治疗(无抗生素天数较多)的预测因素包括血管导管源和凝固酶阴性葡萄球菌菌血症。体温改善在第一周后趋于平稳;白细胞计数、多器官功能障碍评分和血管加压素依赖性在第二周仍持续下降。在 72 例存活至 10 天的患者中,接受较短和较长治疗的患者的临床结局相似。
血流感染患者的抗生素治疗持续时间差异很大,且通常较长。需要进行随机试验来确定治疗时间,以最大限度地提高治愈率,同时最大限度地减少抗生素的不良后果。